|Marek L. Kowalski, Ewa Smorawska, Sławomir W. Kosiński|
Katedra i Zakład Immunologii Klinicznej Akademii Medycznej
Ośrodek Diagnostyki i Leczenia Astmy i Alergii Katedry Immunologii AM i PSK Nr 2 Akademii Medycznej, ul. Mazowiecka 11, 52-215 Łódź
The aim of the study was to assess the effectiveness and safety of the treatment of bronchial asthma exacerbations with nebulised salbutamol in out-patients.
37 cases of bronchial asthma exacerbation reported in 18 patients treated in 1996 and 1997 at the Center for Diagnosis and Treatment of Asthma and Allergy, Medical University of LódY have been analyzed retrospectively. Severity of exacerbation was assessed based on the case history, clinical examination, measurement of the PEFR and O2-saturation. Initially every patient received 2,5 mg of salbutamol in oxygen nebulisation during 20 minutes and following doses of salbutamol were given every 20 minutes according to the clinical response. Simultanously, patients received oral or intravenous cortocosteroids. Before treatment the mean value of the PEFR was 47% of predicted (range 32-82 %), mean respiration rate was 20/min and mean heart rate was 100/min. In 29 cases of bronchial asthma exacerbation nebulisation of the first dose of salbutamol resulted in the relieve of asthmatic symptoms with simultaneous increase of the PEFR value (from mean 49% to mean 72% of predicted). In 5 patients disappearance of symptoms was achived following the 2 nd nebulisation while in 3 cases - following the 3 rd one. A clinical recovery and a lung function improvement were observed together with the decrease of the respiration rate and heart rate. In all patients satisfactory improvement was obtained and no one required hospitalisation.
Our study indicates that nebulisation of sympathomimetics is an effective and safe method of treatment of bronchial asthma exacerbation.
pages: from 35 to 40
|estimated time of download (80 kB)|